The estimated Net Worth of Capital Advisors, Llc Conra... is at least $2.79 Milhão dollars as of 28 January 2020. Capital Conra owns over 58,399 units of ENDRA Life Sciences Inc stock worth over $944,330 and over the last 6 years Capital sold NDRA stock worth over $1,843,304.
Capital has made over 4 trades of the ENDRA Life Sciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital sold 58,399 units of NDRA stock worth $160,597 on 28 January 2020.
The largest trade Capital's ever made was selling 211,668 units of ENDRA Life Sciences Inc stock on 21 January 2020 worth over $607,487. On average, Capital trades about 144,060 units every 116 days since 2018. As of 28 January 2020 Capital still owns at least 3,777,318 units of ENDRA Life Sciences Inc stock.
You can see the complete history of Capital Conra stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 1312 CEDAR STREET1312 CEDAR STREET, , SANTA MONICA,SANTA MONICA,, CACA, 9040590405.
Over the last 8 years, insiders at ENDRA Life Sciences Inc have traded over $893,199 worth of ENDRA Life Sciences Inc stock and bought 413,648 units worth $301,877 . The most active insiders traders include Group Ag Ubs, Capital Advisors, Llc Conra..., eAlexander Y Tokman. On average, ENDRA Life Sciences Inc executives and independent directors trade stock every 61 days with the average trade being worth of $5,922. The most recent stock trade was executed by Group Ag Ubs on 27 August 2024, trading 3,715 units of NDRA stock currently worth $2,043.
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.
ENDRA Life Sciences Inc executives and other stock owners filed with the SEC include: